By looking into the mechanism we found that consistent with the presence of Th9 cells in the tumor of NSCLC patients, targeted deletion of IL-9 resulted in significant upregulation of IL-21, a cytokine produced by Th9 cells that may regulate anti-tumor effects of Th9 cells in lung cancer (Figure 6J). The gene discussed is IL21; the disease is lung carcinoma.